

Global Viral Vector Vaccines Market Report and Forecast 2024-2032

Market Report | 2023-09-07 | 160 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$5999.00

Report description:

Global Viral Vector Vaccines Market and Forecast 2024-2032

Global Viral Vector Vaccines Market Outlook

The global viral vector vaccines market size was valued at USD 820.0 million in 2023, driven by the rapid advances in vaccine technology and the ongoing development of vaccines against infectious diseases and cancers. The market size is anticipated to grow at a CAGR of 19.6% during the forecast period of 2024-2032 to achieve a value of USD 4,098.9 million by 2032.

Viral Vector Vaccines: Introduction

Viral vector vaccines represent an innovative approach to vaccination that has gained significant attention, especially in the context of emerging infectious diseases and the ongoing global efforts to combat various pathogens. These vaccines use a harmless virus, known as a viral vector, as a delivery system to introduce genetic material from a target pathogen into the human body. This genetic material stimulates the immune system to produce a protective response against the target pathogen.

Significance of Viral Vector Vaccines:

Viral vector vaccines are significant because they offer a versatile and effective platform for developing vaccines against a wide range of infectious diseases, including viral infections and certain cancers. They are particularly valuable in situations where traditional vaccine development methods may face challenges.

Key Trends in the Global Viral Vector Vaccines Market

- Expanding Vaccine Development Platforms: Researchers are exploring a variety of viral vectors, including adenoviruses, vesicular stomatitis viruses (VSVs), and adeno-associated viruses (AAVs), for vaccine development. This diversity allows for targeting a wide range of diseases, including infectious diseases and certain cancers.
- COVID-19 Vaccine Development and Beyond: The COVID-19 pandemic has accelerated the development and adoption of viral vector vaccines. The success of COVID-19 vaccines using viral vectors has sparked interest in applying this technology to other infectious diseases, such as HIV and influenza.
- Cancer Vaccines: Viral vector vaccines are being investigated as a tool in cancer immunotherapy. They can deliver tumor-specific antigens or genetic material to trigger an immune response against cancer cells. The market for cancer vaccines is expected to grow as more research and clinical trials take place.
- Gene Therapies: Viral vectors are not limited to vaccines; they are also essential in gene therapy applications. As gene therapy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

becomes more common in treating genetic disorders, viral vectors are playing a crucial role in delivering therapeutic genes.

Global Viral Vector Vaccines Market Segmentations

The market can be categorised into type, application, disease, end user and region.

Market Breakup by Type

- Adenovirus
- Retrovirus
- Plasmid DNA
- AAV
- Lentivirus
- Others

Market Breakup by Application

- Antisense and RNAi
- Gene Therapy
- Cell Therapy
- Vaccinology

Market Breakup by Disease

- Cancer
- Genetic Disorders
- Infectious Diseases
- Others

Market Breakup by End User

- Pharmaceutical
- Biopharmaceutical Companies
- Research Institute

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Global Viral Vector Vaccines Market Overview

The global viral vector vaccines market is a rapidly growing segment within the broader vaccine industry. Viral vector vaccines use harmless viruses as vehicles, or vectors, to deliver genetic material from a target pathogen into the human body. This genetic material stimulates an immune response and triggers the production of antibodies and immune memory cells, providing protection against specific diseases. The global viral vector vaccines market has witnessed substantial growth in recent years, and this trend is expected to continue. Factors contributing to market growth include advances in vaccine technology, increasing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

investment in research and development, and the urgent need for vaccines against emerging infectious diseases.

North America and Europe are major players in the global viral vector vaccines market due to their advanced healthcare infrastructure, robust research and development capabilities, and substantial investment in vaccine development. Emerging markets in Asia Pacific and Latin America are showing significant growth potential, driven by increasing healthcare awareness and infrastructure development.

Key Players in the Global Viral Vector Vaccines Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in global viral vector vaccines market are as follows:

- [] Novasep
- [] Merck KGaA
- [] Charles River Laboratories
- [] uniQure N.V
- [] Waisman Biomanufacturing
- [] Creative-Biogene
- [] Aldevron
- [] Addgene
- [] Oxford Biomedical
- [] Thermo Fisher Scientific Inc

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Viral Vector Vaccines Market Overview
- 3.1 Global Viral Vector Vaccines Market Historical Value (2017-2023)
- 3.2 Global Viral Vector Vaccines Market Forecast Value (2024-2032)
- 4 Global Viral Vector Vaccines Market Landscape
- 4.1 Global Viral Vector Vaccines: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Viral Vector Vaccines: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Disease
- 4.2.3 Analysis by Applications
- 5 Global Viral Vector Vaccines Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter's Five Forces Model
- 5.4 Key Demand Indicators

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.5Key Price Indicators
- 5.6Industry Events, Initiatives, and Trends
- 5.7Value Chain Analysis
- 6Global Viral Vector Vaccines Market Segmentation
 - 6.1Global Viral Vector Vaccines Market by Type
 - 6.1.1Market Overview
 - 6.1.2Adenovirus
 - 6.1.3Retrovirus
 - 6.1.4Plasmid DNA
 - 6.1.5AAV
 - 6.1.6Lentivirus
 - 6.1.7Others
 - 6.2Global Viral Vector Vaccines Market by Applications
 - 6.2.1Market Overview
 - 6.2.2Antisense and RNAi
 - 6.2.3Gene Therapy
 - 6.2.4Cell Therapy
 - 6.2.5Vaccinology
 - 6.3Global Viral Vector Vaccines Market by Disease
 - 6.3.1Market Overview
 - 6.3.2Cancer
 - 6.3.3Genetic Disorders
 - 6.3.4Infectious Diseases
 - 6.3.5Others
 - 6.4Global Viral Vector Vaccines Market by End User
 - 6.4.1Market Overview
 - 6.4.2Pharmaceutical
 - 6.4.3Biopharmaceutical Companies
 - 6.4.4Research Institute
 - 6.5Global Viral Vector Vaccines Market by Region
 - 6.5.1Market Overview
 - 6.5.2North America
 - 6.5.3Europe
 - 6.5.4Asia Pacific
 - 6.5.5Latin America
 - 6.5.6Middle East and Africa
- 7North America Viral Vector Vaccines Market
 - 7.1Market Share by Country
 - 7.2United States of America
 - 7.3Canada
- 8Europe Viral Vector Vaccines Market
 - 8.1Market Share by Country
 - 8.2United Kingdom
 - 8.3Germany
 - 8.4France
 - 8.5Italy
 - 8.6Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9Asia Pacific Viral Vector Vaccines Market
 - 9.1Market Share by Country
 - 9.2China
 - 9.3Japan
 - 9.4India
 - 9.5ASEAN
 - 9.6Australia
 - 9.7Others
- 10Latin America Viral Vector Vaccines Market
 - 10.1Market Share by Country
 - 10.2Brazil
 - 10.3Argentina
 - 10.4Mexico
 - 10.5Others
- 11Middle East and Africa Viral Vector Vaccines Market
 - 11.1Market Share by Country
 - 11.2Saudi Arabia
 - 11.3United Arab Emirates
 - 11.4Nigeria
 - 11.5South Africa
 - 11.6Others
- 12Regulatory Framework
 - 12.1Regulatory Overview
 - 12.1.1US FDA
 - 12.1.2EU EMA
 - 12.1.3INDIA CDSCO
 - 12.1.4JAPAN PMDA
 - 12.1.5Others
- 13Patent Analysis
 - 13.1Analysis by Type of Patent
 - 13.2Analysis by Publication year
 - 13.3Analysis by Issuing Authority
 - 13.4Analysis by Patent Age
 - 13.5Analysis by CPC Analysis
 - 13.6Analysis by Patent Valuation
 - 13.7Analysis by Key Players
- 14Grants Analysis
 - 14.1Analysis by year
 - 14.2Analysis by Amount Awarded
 - 14.3Analysis by Issuing Authority
 - 14.4Analysis by Grant Application
 - 14.5Analysis by Funding Institute
 - 14.6Analysis by NIH Departments
 - 14.7Analysis by Recipient Organization
- 15Clinical Trials Analysis
 - 15.1 Analysis by Trial Registration Year
 - 15.2Analysis by Trial Status

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.3Analysis by Trial Phase
- 15.4Analysis by Therapeutic Area
- 15.5Analysis by Geography
- 16Funding and Investment Analysis
 - 16.1Analysis by Funding Instances
 - 16.2Analysis by Type of Funding
 - 16.3Analysis by Funding Amount
 - 16.4Analysis by Leading Players
 - 16.5Analysis by Leading Investors
 - 16.6Analysis by Geography
- 17Partnership and Collaborations Analysis
 - 17.1Analysis by Partnership Instances
 - 17.2Analysis by Type of Partnership
 - 17.3Analysis by Leading Players
 - 17.4Analysis by Geography
- 18Supplier Landscape
 - 18.1Novasep
 - 18.1.1Financial Analysis
 - 18.1.2Product Portfolio
 - 18.1.3Demographic Reach and Achievements
 - 18.1.4Mergers and Acquisitions
 - 18.1.5Certifications
 - 18.2Merck KGaA
 - 18.2.1Financial Analysis
 - 18.2.2Product Portfolio
 - 18.2.3Demographic Reach and Achievements
 - 18.2.4Mergers and Acquisitions
 - 18.2.5Certifications
 - 18.3Charles River Laboratories
 - 18.3.1Financial Analysis
 - 18.3.2Product Portfolio
 - 18.3.3Demographic Reach and Achievements
 - 18.3.4Mergers and Acquisitions
 - 18.3.5Certifications
 - 18.4uniQure N.V
 - 18.4.1Financial Analysis
 - 18.4.2Product Portfolio
 - 18.4.3Demographic Reach and Achievements
 - 18.4.4Mergers and Acquisitions
 - 18.4.5Certifications
 - 18.5Waisman Biomanufacturing
 - 18.5.1Financial Analysis
 - 18.5.2Product Portfolio
 - 18.5.3Demographic Reach and Achievements
 - 18.5.4Mergers and Acquisitions
 - 18.5.5Certifications
 - 18.6Creative-Biogene

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.6.1Financial Analysis
- 18.6.2Product Portfolio
- 18.6.3Demographic Reach and Achievements
- 18.6.4Mergers and Acquisitions
- 18.6.5Certifications
- 18.7Aldevron
 - 18.7.1Financial Analysis
 - 18.7.2Product Portfolio
 - 18.7.3Demographic Reach and Achievements
 - 18.7.4Mergers and Acquisitions
 - 18.7.5Certifications
- 18.8Addgene
 - 18.8.1Financial Analysis
 - 18.8.2Product Portfolio
 - 18.8.3Demographic Reach and Achievements
 - 18.8.4Mergers and Acquisitions
 - 18.8.5Certifications
- 18.9Oxford Biomedical
 - 18.9.1Financial Analysis
 - 18.9.2Product Portfolio
 - 18.9.3Demographic Reach and Achievements
 - 18.9.4Mergers and Acquisitions
 - 18.9.5Certifications
- 18.10Thermo Fisher Scientific Inc
 - 18.10.1Financial Analysis
 - 18.10.2Product Portfolio
 - 18.10.3Demographic Reach and Achievements
 - 18.10.4Mergers and Acquisitions
 - 18.10.5Certifications
- 19Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20Company Competitiveness Analysis (Additional Insight)
 - 20.1Very Small Companies
 - 20.2Small Companies
 - 20.3Mid-Sized Companies
 - 20.4Large Companies
 - 20.5Very Large Companies
- 21Payment Methods (Additional Insight)
 - 21.1Government Funded
 - 21.2Private Insurance
 - 21.3Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Viral Vector Vaccines Market Report and Forecast 2024-2032

Market Report | 2023-09-07 | 160 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2999.00
	Five User License	\$3999.00
	Corporate License	\$5999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com